About Aprea Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.aprea.com/
Frequently Asked Questions
What is the 52-week range for APRE?
The 52-week high is $1.69 and the 52-week low is $0.548.
What is the P/E ratio for APRE?
The P/E ratio data is currently unavailable.
What is the dividend yield for APRE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.30%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4409.14%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.45.
Analyst Recommendation Trends
Wall Street analyst consensus for APRE over the last few months:
Latest APRE News
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentatio
Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics
Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain."We look forward to
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026. Pre
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-16 | BIZZARI JEAN-PIERRE | +12,555 | - | - |
| 2026-06-16 | BIZZARI JEAN-PIERRE | +3,135 | - | - |
| 2026-06-16 | HENNEMAN JOHN B III | +12,555 | - | - |
| 2026-06-16 | HENNEMAN JOHN B III | +3,135 | - | - |
| 2026-03-31 | Hamill John P. | +30,978 | - | - |
| 2026-03-31 | Hamill John P. | +30,978 | $0.807 | $24,999 |
| 2026-03-31 | Peters Richard | +123,915 | - | - |
| 2026-03-31 | Peters Richard | +123,915 | $0.807 | $99,999 |
| 2026-03-12 | Gilad Oren | +80,700 | - | - |
| 2026-03-12 | Gilad Oren | +20,175 | - | - |
| 2026-03-12 | Hamill John P. | +40,380 | - | - |
| 2026-03-12 | Hamill John P. | +10,095 | - | - |
| 2026-01-30 | Gilad Oren | +28,100 | - | - |
| 2026-01-30 | Gilad Oren | +28,100 | $0.89 | $25,009 |
| 2026-01-30 | Hamill John P. | +5,700 | - | - |
| 2026-01-30 | Hamill John P. | +5,700 | $0.89 | $5,073 |
| 2025-12-10 | Duey Marc | +21,459 | - | - |
| 2025-12-10 | Duey Marc | +21,459 | $1.165 | $25,000 |
| 2025-12-10 | Gilad Oren | +21,459 | - | - |
| 2025-12-10 | Gilad Oren | +21,459 | $1.165 | $25,000 |
| 2025-12-10 | Hamill John P. | +5,000 | - | - |
| 2025-12-10 | Hamill John P. | +5,000 | $1.165 | $5,825 |